Northwest falls after cash update

Northwest Biotherapeutics (OTCBB:NWBO; LSE:NWBS) fell $0.95 (56%) to $0.75 on Wednesday after announcing that it has only enough cash to support operations through the end of September. The company said it needs to raise "significant" additional capital to fund its trials and other operating activities and to repay indebtedness. Northwest said it is in discussions with several parties regarding additional financing.

Northwest also announced that it received a $1 million loan from Toucan Partners. As of Aug. 19, Northwest had $1.1 million in cash, including the loan. ...